FDLI Virtual Program: What Patient Organizations Should Know to Interact with FDA During COVID-19
September 2, 2020
On September 2, Axinn partner Chad Landmon participated in an FDLI virtual program entitled, "What Patient Organizations Should Know to Interact with FDA During COVID-19."
Panelists provided an overview of FDA’s COVID-19 medical product response and addressed the impact of the pandemic on medical product development and FDA priorities and personnel.